FDA Adverse Event Malfunction Summary report: N

INRATIO

MDR report key: 1028092 · Received April 11, 2008

Report

Report Number
2954730-2008-00160
Event Type
Malfunction
Date Received
April 11, 2008
Date of Event
March 12, 2008
Report Date
April 1, 2008
Manufacturer
HEMOSENSE SJ
Product Code
JPA
Product Problem
Yes
Report Source
Manufacturer report
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

DISCREPANT RESULTS (ACCURACY) COMPARISON OF INRATIO TEST WITH LAB RESULTS PROVIDED BY END-USER AT TIME COMPLAINT WAS FILED: DATE: UNKNOWN, INRATIO: 2.3, LAB: 2.9, MEAN: 2.6, CONFIDENCE LIMITS: 1.7 - 3.8. DATE: 2008, INRATIO: 4.2, LAB: 3.3, MEAN: 3.75, CONFIDENCE LIMITS: 2.2 - 5.3. DATE: A WEEK LATER, INRATIO: 3.4, LAB: 2.5, MEAN: 3.0, CONFIDENCE LIMITS: 1.8 - 4.2. DATE: THE SAME DAY, INRATIO: 3.1, LAB: 2.5, MEAN: 2.8, CONFIDENCE LIMITS: 1.8 - 4.2. PER INTERNAL PROCEDURE, THE MEAN OF THE INRATIO METER AND COMPARATIVE SYSTEM INR WERE CALCULATED. FOR ALL 4 DATA SETS, BOTH INRATIO AND LAB VALUES ARE WITHIN THE CONFIDENCE LIMITS FOR INR TESTING. THE RESULTS ARE CONSIDERED NOT DISCREPANT WITHIN THE CONTEXT OF THE DOCUMENTED VARIABILITY FOR INR TESTING. THEREFORE, FURTHER TESTING IS NOT REQUIRED AT THIS TIME. INRATIO PRECISION DATA PROVIDED BY END-USER LOT: 070533. FIRST TEST INR = 3.4; SECOND INR = 3.1. MEAN = 3.25; SD = 0.21; %CV = 6.52. THE %CV IS LESS THAN 20%. PER INTERNAL PROCEDURE, THE PRECISION PASSES THE CRITERIA FOR PRECISION. THE TEST IS CONSIDERED PRECISE AND FURTHER TESTING IS REQUIRED AT THIS TIME.

Description of Event or Problem · 1

CALLER ALLEGES INACCURACY WITH INRATIO. RESULTS AS FOLLOWS: DATE: UNKNOWN, INRATIO: 2.3, LAB: 2.9; DATE: 2008, INRATIO: 4.2, LAB: 3.3 DATE: A WEEK LATER, INRATIO: 3.4, LAB: 2.5; DATE: THE SAME DAY, INRATIO: 3.1, LAB: 2.5. CALLER ALLEGES IMPRECISION WITH INRATIO. RESULTS AS FOLLOWS: FIRST TEST INR = 3.4; SECOND TEST INR = 3.1.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 INRATIO PROTHROMBIN TIME TEST JPA HEMOSENSE SJ BOXED STRIPS, 12-PK, MULTILANGUA 070533

Patients

Seq Age Sex Outcome Treatment
1